LY3074828

( DrugBank: - / KEGG DRUG: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
37	Generalised pustular psoriasis	1
96	Crohn disease	37

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	67

37. Generalised pustular psoriasis

Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-184065	22/8/2018	15/08/2018	I6T-MC-AMAJ	A Multicenter Randomized Double-Blind Placebo-Controlled Study Comparing the Efficacy and Safety of ...	Psoriasis valgaris, Generalized pustular psoriasis, Erythrodermic psoriasis	Intervention name : LY3074828 INN of the intervention : mirikizumab Dosage And administration of the i ...	Eli Lilly Japan K.K.	NULL	complete	20		BOTH	120	Phase 3	Japan, Asia except Japan, North America, South America, Europe, Oceania

First Previous1Next Last

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

trials per page:

Showing 1 to 10 of 37 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05509777 (ClinicalTrials.gov)	August 1, 2023	19/8/2022	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)	A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disea ...	Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	NULL	Not yet recruiting	2 Years	17 Years	All	90	Phase 3	NULL
2	EUCTR2019-002687-27-DK (EUCTR)	08/04/2022	08/11/2021	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Product Name: MIRIKIZUMAB Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	Serbia;United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India ...
3	EUCTR2019-002687-27-HR (EUCTR)	10/03/2022	14/03/2022	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Product Name: MIRIKIZUMAB Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	Serbia;United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India ...
4	EUCTR2019-002687-27-LT (EUCTR)	03/09/2021	29/06/2021	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Product Name: MIRIKIZUMAB Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	Serbia;United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India ...
5	JPRN-jRCT2031210210	16/08/2021	28/07/2021	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Dise ...	A master protocol for a Phase 3, multicenter, open-label, long-term extension study to evaluate the ...	Ulcerative Colitis / Crohn's Disease -	Drug: Mirikizumab Administered SC Other Name: LY3074828	Yoshimoto Yusuke	NULL	Recruiting	Not applicable	Not applicable	Both	5	Phase 3	United States;Japan
6	EUCTR2019-002687-27-DE (EUCTR)	27/07/2021	13/04/2021	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Product Name: MIRIKIZUMAB Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	Serbia;United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India ...
7	EUCTR2019-002687-27-LV (EUCTR)	17/06/2021	11/03/2021	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Product Name: MIRIKIZUMAB Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	France;Australia;Denmark;Netherlands;Latvia;China;Korea, Republic of;Czechia;Turkey;Lithuania;Austri ...
8	EUCTR2019-002687-27-FR (EUCTR)	10/06/2021	04/05/2021	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Product Name: MIRIKIZUMAB Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	Serbia;United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India ...
9	NCT04844606 (ClinicalTrials.gov)	May 26, 2021	12/4/2021	A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerati ...	A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the ...	Ulcerative Colitis;Ulcerative Colitis Chronic;Inflammatory Bowel Diseases;Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	NULL	Recruiting	2 Years	19 Years	All	150	Phase 3	Israel;Italy;Japan;United States;Korea, Republic of;Poland
10	EUCTR2019-002687-27-IT (EUCTR)	18/05/2021	30/07/2021	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and ...	Crohn´s Disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: MIRIKIZUMAB Product Code: [LY3074828] INN or Proposed INN: MIRIKIZUMAB Product Name: MIRI ...	ELI LILLY & COMPANY, LILLY CORPORATE CENTER	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	778	Phase 3	United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;India;France ...

First Previous1 2 3 4Next Last

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

trials per page:

Showing 1 to 10 of 67 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05767021 (ClinicalTrials.gov)	April 21, 2023	8/2/2023	A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Col ...	A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relations ...	Ulcerative Colitis Chronic;Ulcerative Colitis	Drug: Mirikizumab	Eli Lilly and Company	NULL	Not yet recruiting	18 Years	N/A	All	160	Phase 3	NULL
2	JPRN-jRCT2031210210	16/08/2021	28/07/2021	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Dise ...	A master protocol for a Phase 3, multicenter, open-label, long-term extension study to evaluate the ...	Ulcerative Colitis / Crohn's Disease -	Drug: Mirikizumab Administered SC Other Name: LY3074828	Yoshimoto Yusuke	NULL	Recruiting	Not applicable	Not applicable	Both	5	Phase 3	United States;Japan
3	NCT04844606 (ClinicalTrials.gov)	May 26, 2021	12/4/2021	A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerati ...	A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the ...	Ulcerative Colitis;Ulcerative Colitis Chronic;Inflammatory Bowel Diseases;Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	NULL	Recruiting	2 Years	19 Years	All	150	Phase 3	Israel;Italy;Japan;United States;Korea, Republic of;Poland
4	NCT04469062 (ClinicalTrials.gov)	April 20, 2021	10/7/2020	A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through St ...	Ulcerative Colitis	Drug: Mirikizumab IV;Drug: Mirikizumab SC;Drug: Vedolizumab IV;Drug: Placebo IV;Drug: Placebo SC	Eli Lilly and Company	NULL	Withdrawn	18 Years	80 Years	All	0	Phase 3	NULL
5	EUCTR2019-001653-99-BE (EUCTR)	26/02/2021	26/02/2021	A placebo-controlled study of mirikizumab and vedolizumab in participants withmoderately to severely ...	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-Controlled Treat-Through Stu ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: mirikizumab Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Not Recruiting			Female: yes Male: yes	1100	Phase 3	Spain;Ukraine;Russian Federation;Switzerland;Italy;India;France;Malaysia;Australia;Denmark;South Afr ...
6	EUCTR2019-001653-99-LT (EUCTR)	01/02/2021	23/09/2020	A placebo-controlled study of mirikizumab and vedolizumab in participants withmoderately to severely ...	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-Controlled Treat-Through Stu ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: mirikizumab Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Not Recruiting			Female: yes Male: yes	1100	Phase 3	Italy;India;France;Malaysia;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Tur ...
7	EUCTR2019-001653-99-LV (EUCTR)	18/01/2021	26/10/2020	A placebo-controlled study of mirikizumab and vedolizumab in participants withmoderately to severely ...	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-Controlled Treat-Through Stu ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: mirikizumab Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Not Recruiting			Female: yes Male: yes	1100	Phase 3	United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Russian Federation;Switzerland;Italy;India;Fran ...
8	EUCTR2019-001653-99-AT (EUCTR)	12/01/2021	24/11/2020	A placebo-controlled study of mirikizumab and vedolizumab in participants withmoderately to severely ...	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-Controlled Treat-Through Stu ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: mirikizumab Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Not Recruiting			Female: yes Male: yes	1100	Phase 3	United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Russian Federation;Switzerland;Italy;India;Fran ...
9	EUCTR2019-001653-99-DE (EUCTR)	08/01/2021	05/10/2020	A placebo-controlled study of mirikizumab and vedolizumab in participants withmoderately to severely ...	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-Controlled Treat-Through Stu ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: mirikizumab Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Not Recruiting			Female: yes Male: yes	1100	Phase 3	Portugal;Serbia;United States;Slovakia;Spain;Ukraine;Russian Federation;Switzerland;Italy;India;Fran ...
10	EUCTR2019-001653-99-FR (EUCTR)	26/11/2020	12/10/2020	A placebo-controlled study of mirikizumab and vedolizumab in participants withmoderately to severely ...	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-Controlled Treat-Through Stu ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: mirikizumab Product Code: LY3074828 INN or Proposed INN: MIRIKIZUMAB Other descriptive na ...	Eli Lilly and Company	NULL	Not Recruiting			Female: yes Male: yes	1100	Phase 3	Malaysia;Denmark;United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Russian Federation;Switzerland ...

First Previous1 2 3 4 5 6 7Next Last